Table 1 HER-2/neu amplification status by multiplex ligation-dependent probe amplification (MLPA) of 42 breast cancer patients in undissected sections and after manual and laser microdissection, in comparison with in situ hybridization and immunohistochemistry.
MLPA | |||||||
|---|---|---|---|---|---|---|---|
Case number | IHC | ISH | Undissected | Manual MD | Laser MD | DCIS | Tumor % |
1 | 0 | NA | 1 | 1 | 1 | Yes | 30 |
2 | 0 | NA | 1 | 1 | 1 | 30 | |
3 | 0 | NA | 1 | 1 | 1 | Yes | 10 |
4 | 2 | NA | 1 | 1 | 1 | 10 | |
5 | 2 | NA | 1 | 1 | 1 | Yes | 70 |
6 | 2 | NA | 1 | 1 | 2 | Yes | 70 |
7 | 2 | NA | 1 | 1 | 1 | 50 | |
8 | 2 | NA | 1 | 1 | 1 | 70 | |
9 | 2 | NA | 1 | 1 | 1 | 70 | |
10 | 2 | NA | 1 | 1 | 1 | 60 | |
11 | 2 | NA | 1 | 1 | 1 | 30 | |
12 | 2 | NA | 1 | 1 | 1 | 60 | |
13 | 1 | LA | 2 | 2 | 2 | 70 | |
14 | 2 | A | 2 | 3 | 3 | 80 | |
15 | 2 | A | 2 | 2 | 3 | Yes | 80 |
16 | 3 | A | 2 | 2 | 3 | 80 | |
17 | 2 | LA | 2 | 2 | 3 | 80 | |
18 | 0 | NA | 2 | 1 | 1 | Yes | 90 |
19 | 0 | NA | 2 | 1 | 1 | 80 | |
20 | 1 | A | 2 | 3 | 3 | 70 | |
21 | 1 | LA | 2 | 3 | 2 | Yes | 50 |
22 | 1 | NA | 2 | 2 | 1 | Yes | 80 |
23 | 1 | NA | 2 | 1 | 1 | Yes | 10 |
24 | 1 | NA | 2 | 1 | 1 | Yes | 60 |
25 | 0 | NA | 3 | 1 | 1 | 60 | |
26 | 0 | NA | 3 | 1 | 1 | 80 | |
27 | 1 | A | 3 | 3 | 3 | 70 | |
28 | 1 | NA | 3 | 3 | 3 | Yes | 30 |
29 | 3 | A | 3 | 3 | 3 | 50 | |
30 | 1 | A | 3 | 3 | 3 | 80 | |
31 | 2 | A | 3 | 3 | 3 | Yes | 70 |
32 | 3 | A | 3 | 3 | 3 | Yes | 80 |
33 | 3 | A | 3 | 3 | 3 | 20 | |
34 | 3 | A | 3 | 3 | 3 | 70 | |
35 | 3 | A | 3 | 3 | 3 | 80 | |
36 | 3 | A | 3 | 3 | 3 | 70 | |
37 | 3 | A | 3 | 3 | 3 | 30 | |
38 | 3 | A | 3 | 3 | 3 | 70 | |
39 | 3 | A | 3 | 3 | 3 | 60 | |
40 | 2 | A | 3 | 3 | 3 | Yes | 40 |
41 | 3 | A | 3 | 3 | 3 | Yes | 20 |
42 | 3 | A | 3 | 3 | 3 | 10 | |